drugset
drugset / Trial / NCT00441883

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883 ↗

Phase 2 Completed 176 enrolled Bausch & Lomb Incorporated NicOx Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of PF 03187207.

Timeline

Start
2007-03
Primary completion
2008-02
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Other
Subject PF-03187207 Unknown — Other

Indications

exfoliation syndrome ocular hypertension open-angle glaucoma